A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high - dose interferon for <font color="blue">melanoma_1</font> <font color="blue">._1</font> 
<br>
<br> PURPOSE Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter , randomized trials , conducted by the Eastern Cooperative Oncology Group and the Intergroup , investigating adjuvant high - dose IFN - alpha 2b therapy . The objectives of this study were to <font color="blue">update_1</font> <font color="blue">the_1</font> <font color="blue">analyses_1</font> <font color="blue">of_1</font> <font color="blue">each_1</font> <font color="blue">individual_1</font> <font color="blue">trial_1</font> <font color="blue">and_1</font> <font color="blue">to_1</font> <font color="blue">analyze_1</font> <font color="blue">prognostic_1</font> <font color="blue">factors_1</font> <font color="blue">and_1</font> <font color="blue">treatment_1</font> <font color="blue">effects_1</font> based on pooled data . 
<br> EXPERIMENTAL DESIGN <font color="blue">Survival_1</font> <font color="blue">and_1</font> <font color="blue">disease_1</font> <font color="blue">status_1</font> were updated to April 2001 . <font color="blue">Analysis_1</font> <font color="blue">of_1</font> <font color="blue">prognostic_1</font> <font color="blue">factors_1</font> <font color="blue">using_1</font> <font color="blue">optimized_1</font> <font color="blue">statistical_1</font> <font color="blue">models_1</font> was based on data from patients in E1684 , E1690 , E1694 , and E2696 . <font color="blue">Analysis_1</font> <font color="blue">of_1</font> <font color="blue">treatment_1</font> <font color="blue">effects_1</font> <font color="blue">versus_1</font> <font color="blue">observation_1</font> <font color="blue">(_1</font> <font color="blue">Obs_1</font> <font color="blue">)_1</font> was based on data from 713 patients randomized to high - dose IFN - alpha 2b ( HDI ) or Obs in Trials E1684 and E1690 . 
<br> RESULTS Updated analysis of E1684 , E1690 , and E1694 confirmed their original conclusions , now at median follow - up intervals of 2.1 - 12.6 years . Based on two - sided univariate log - rank analysis of pooled data from E1684 and E1690 ( median follow - up , 7.2 years ) , <font color="blue">relapse_1</font> <font color="blue">-_1</font> <font color="blue">free_1</font> <font color="blue">survival_1</font> <font color="blue">(_1</font> <font color="blue">RFS)-but_1</font> not <font color="blue">overall_1</font> <font color="blue">survival_1</font> <font color="blue">(_1</font> <font color="blue">OS)-was_1</font> significantly prolonged ( two - sided log - rank P value = 0.006 ) for patients treated with HDI versus Obs . Among all patients , prognostic factors that significantly negatively impacted <font color="blue">RFS_1</font> <font color="blue">and_1</font> <font color="blue">OS_1</font> included ulceration , recurrent disease at entry , enrollment in E1684 , and age > 49 years . Multivariate statistical models adjusting for these factors confirmed the statistically significant <font color="blue">RFS_1</font> benefit of HDI versus Obs but did not demonstrate a significant <font color="blue">OS_1</font> benefit in the pooled populations . 
<br> CONCLUSIONS In patients with high - risk resected melanoma , HDI is effective adjuvant therapy with strong evidence for <font color="blue">improved_1</font> <font color="blue">RFS_2</font> <font color="blue">and_1</font> <font color="blue">evidence_1</font> <font color="blue">for_1</font> <font color="blue">moderate_1</font> <font color="blue">improvement_1</font> <font color="blue">in_1</font> <font color="blue">OS_2</font> based on two prospective randomized studies but not the pooled analysis . Analyses of predictors of relapse and response are now needed to improve the therapeutic value of this modality .